Chronic fluoxetine treatment affects gene expression of catecholamine enzymes in the heart of depression model rats

Indian Journal of Experimental Biology

Volumn 50, Issue 11, 2012, Pages 771-775

  Spasojevic, Natasa ^a   Jovanovic, Predrag ^a   Dronjak, Sladjana ^a  

^a UNIVERSITY OF BELGRADE   (Serbia)

Author keywords

Antidepressant; Catecholamine enzymes; Depression; Gene expression; Heart

Indexed keywords

CATECHOLAMINE; DOPAMINE BETA MONOOXYGENASE; FLUOXETINE; PHENYLETHANOLAMINE N METHYLTRANSFERASE; SEROTONIN UPTAKE INHIBITOR; TYROSINE 3 MONOOXYGENASE;

ANIMAL; ARTICLE; BIOSYNTHESIS; DEPRESSION; DISEASE MODEL; DRUG EFFECT; ENZYMOLOGY; GENE EXPRESSION; GENETICS; HEART ATRIUM; HEART VENTRICLE; MALE; MENTAL STRESS; RAT; REAL TIME POLYMERASE CHAIN REACTION; TIME; WISTAR RAT;

ANIMALS; CATECHOLAMINES; DEPRESSION; DISEASE MODELS, ANIMAL; DOPAMINE BETA-HYDROXYLASE; FLUOXETINE; GENE EXPRESSION; HEART ATRIA; HEART VENTRICLES; MALE; PHENYLETHANOLAMINE N-METHYLTRANSFERASE; RATS; RATS, WISTAR; REAL-TIME POLYMERASE CHAIN REACTION; SEROTONIN UPTAKE INHIBITORS; STRESS, PSYCHOLOGICAL; TIME FACTORS; TYROSINE 3-MONOOXYGENASE;

ANIMALIA; RATTUS;

EID: 84869010898     PISSN: 00195189     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (46)

1. Belmaker R H & Agam G, Major depressive disorder, N Engl J Med, 358 (2008) 55.
2. Hammen C, Stress and depression, Annu Rev Clin Psychol, 1 (2005) 293.
3. Bayles R G, Dawood T, Lambert E A, Schlaich M P & Lambert G W, Elevated cardiac risk in patients with major depressive disorder, Am J Psychiatry, 165 (2008) 137.
4. Surtees P G, Wainwright N W, Boekholdt S M, Luben R N, Wareham N J & Khaw K T, Major depression, C-reactive protein, and incident ischemic heart disease in healthy men and women, Psychosom Med, 70 (2008) 850.
5. Jiang W, Glassman A, Krishnan R, O'Connor C M & Califf R M, Depression and ischemic heart disease: what have we learned so far and what must we do in the future? Am Heart J, 150 (2005) 54.
6. Lett H S, Blumenthal J A, Babyak M A, Sherwood A, Strauman T, Robins C & Newman M F, Depression as a risk factor for coronary artery disease: evidence, mechanisms, and treatment, Psychosom Med, 66 (2004) 305.
7. Lichtman J H, Bigger J T Jr, Blumenthal J A, Frasure-Smith N, Kaufmann P G, Lespérance F, Mark D B, Sheps D S, Taylor C B & Froelicher E S, Depression and coronary heart disease. Recommendations for screening, referral, and treatment, Circulation, 118 (2008) 1768.
8. Cohen H W, Gibson G & Alderman M H, Excess risk of myocardial infarction in patients treated with antidepressant medications: association with use of tricyclic agents, Am J Med, 108 (2000) 2.
9. Kalkan S, Hocaoglu N, Oransay K, Buyukdeligoz M & Tuncok Y, Adenosine-mediated cardiovascular toxicity in amitriptyline-poisoned rats, Drug Chem Toxicol, (2011), doi:10.3109/01480545.2011.640682.
10. Roose S P & Miyazaki M, Pharmacologic treatment of depression in patients with heart disease, Psychosom Med, 67 (2005) 54.
11. Mahesh R, Pandey D K, Katiyar S, Kukade G, Viyogi S & Rudra A, Effect of anti-depressants on neuro-behavioural consequences following impact accelerated traumatic brain injury in rats, Indian J Exp Biol, 48 (2010) 466.
12. Carney R M, Freedland K E & Veith RC, Depression, the autonomic nervous system, and coronary heart disease, Psychosom Med, 67 (2005) 29.
13. Sauer W H, Berlin J A & Kimmel S E, Effect of antidepressants and their relative affinity for the serotonin transporter on the risk of myocardial infarction, Circulation, 108 (2003) 32.
14. Swenson J R, O'Connor C M, Barton D, Van Zyl L T, Swedberg K, Forman L M, Gaffney M & Glassman A H, Influence of depression and effect of treatment with sertraline on quality of life after hospitalization for acute coronary syndrome, Am J Cardiol, 92 (2003) 1271.
15. Alvarez P A & Pahissa J, QT alterations in psychopharmacology: proven candidates and suspects, Curr Drug Saf, 5 (2010) 97.
16. Pacher P, Ungvari Z, Nanasi P P, Furst S & Kecskemeti V, Speculations on difference between tricyclic and selective serotonin reuptake inhibitor antidepressants on their cardiac effects. Is there any? Curr Med Chem, 6 (1999) 469.
17. Kvetnansky R, Sabban E L & Palkovits M, Catecholaminergic systems in stress: structural and molecular genetic approaches, Physiol Rev, 89 (2009) 535.
18. Oliva J M, Uriguen L, Perez-Rial S & Manzanares J, Time course of opioid and cannabinoid gene transcription alterations induced by repeated administration with fluoxetine in the rat brain, Neuropharmacology, 49 (2005) 618.
19. Zhu M Y, Wang W P, Baldessarini R J & Kim K S, Effects of desipramine treatment on tyrosine hydroxylase gene expression in cultured neuroblastoma cells and rat brain tissue, Brain Res Mol Brain Res, 133 (2005) 167.
20. Dronjak S, Spasojevic N, Gavrilovic L & Varagic V, Effects of noradrenaline and serotonin reuptake inhibitors on pituitary-adrenocortical and sympatho-adrenomedullar system of adult rats, Neuro Endocrinol Lett, 28 (2007) 614.
21. Spasojevic N, Gavrilovic L & Dronjak S, Different behavioral effects of maprotiline and fluxilan in rats, Arch Biol Sci, 60 (2008) 33.
22. Grippo A J, Moffitt J A & Johnson A K, Cardiovascular alterations and autonomic imbalance in an experimental model of depression, Am J Physiol Regul Integr Comp Physiol, 282 (2002) 1333.
23. -CTMethod, Methods, 25 (2001) 402.
24. Grippo A J, Beltz T G, Weiss R M & Johnson A K, The effects of chronic fluoxetine treatment on chronic mild stress-induced cardiovascular changes and anhedonia, Biol Psychiatry, 59 (2006) 309.
25. Gavrilovic L, Spasojevic N & Dronjak S, Psychosocial stress-related changes in gene expression of norepinephrine biosynthetic enzymes in stellate ganglia of adult rats, Auton Neurosci, 150 (2009) 144.
26. Parrish D C, Gritman K, VanWinkle D M, Woodward W R, Bader M & Habecker B A, Postinfarct sympathetic hyperactivity differentially stimulates expression of tyrosine hydroxylase and norepinephrine transporter, Am J Physiol Heart Circ Physiol, 294 (2008) 99.
27. Spasojevic N, Jovanovic P, Spasojevic-Tisma V, Djelic N & Dronjak S, Differential in vivo regulation of TH and DBH mRNA in rat atria by maprotiline and fluoxetine, Arch Biol Sci, 63 (2011) 597.
28. Bymaster F P, Zhang W, Carter P A, Shaw J, Chernet E, Phebus L, Wong D T & Perry K W, Fluoxetine, but not other selective serotonin uptake inhibitors, increases norepinephrine and dopamine extracellular levels in prefrontal cortex, Psychopharmacology (Berl), 160 (2002) 353.
29. Perry K W & Fuller R W, Fluoxetine increases norepinephrine release in rat hypothalamus as measured by tissue levels of MHPG-SO4 and microdialysis in conscious rats, J Neural Transm, 104 (1997) 953.
30. Brady L S, Whitfield H J, Jr Fox R J, Gold P W & Herkenham M, Long-term antidepressant administration alters corticotropin-releasing hormone, tyrosine hydroxylase, and mineralocorticoid receptor gene expression in rat brain. Therapeutic implications, J Clin Invest, 87 (1991) 831.
31. Heydendael W & Jacobson L, Widespread hypothalamicpituitary-adrenocortical axis-relevant and mood-relevant effects of chronic fluoxetine treatment on glucocorticoid receptor gene expression in mice, Eur J Neurosci, 31(2010) 892.
32. Spasojevic N, Gavrilovic L & Dronjak S, Effects of repeated maprotiline and fluoxetine treatment on gene expression of catecholamine synthesizing enzymes in adrenal medulla of unstressed and stressed rats, Auton Autacoid Pharmacol, 30 (2010) 213.
33. Duman R S, Role of neurotrophic factors in the etiology and treatment of mood disorders, Neuromolecular Med, 5 (2004) 11.
34. Nibuya M, Nestler E J & Duman R S, Chronic antidepressant administration increases the expression of cAMP response element binding protein (CREB) in rat hippocampus, J Neurosci, 16 (1996) 2365.
35. Shinkai K, Toyohira Y, Yoshimura R, Tsutsui M, Ueno S, Nakamura J & Yanagihara N, Stimulation of catecholamine synthesis via activation of p44/42 MAPK in cultured bovine adrenal medullary cells by milnacipran, Naunyn Schmiedebergs Arch Pharmacol, 375 (2007) 65.
36. Ueyama T, Aki T, Senba E, Hatanaka K & Yoshida K, Emotional stress activates MAP kinase in the rat heart, Life Sci, 69 (2001) 1927.
37. Yasumoto S, Tamura K, Karasawa J, Hasegawa R, Ikeda K, Yamamoto T & Yamamoto H, Inhibitory effect of selective serotonin reuptake inhibitors on the vesicular monoamine transporter 2, Neurosci Lett, 454 (2009) 229.
38. Ellinghaus P, Scheubel R J, Dobrev D, Ravens U, Holtz J, Huetter J, Nielsch U & Morawietz H, Comparing the global mRNA expression profile of human atrial and ventricular myocardium with high-density oligonucleotide arrays, J Thorac Cardiovasc Surg, 129 (2005) 1383.
39. McGrath M F & de Bold A J, Transcriptional analysis of the mammalian heart with special reference to its endocrine function, BMC Genomics, 10 (2009) 254.
40. Tai T C, Claycomb R, Her S, Bloom A K & Wong D L, Glucocorticoid responsiveness of the rat phenylethanolamine-N-methyltransferase gene, Mol Pharmacol, 61 (2002) 1385.
41. Ziegler M G, Kennedy B P, Bao X & Enns R, Ectopic (extraadrenal medullary) phenylethanolamine N-methyltransferase expression, Ann NY Acad Sci, 971 (2002) 76.
42. Spasojevic N, Gavrilovic L, Kovacevic I & Dronjak S, Effects of antidepressants maprotiline and fluxilan on sympatho-adrenomedullary system in stressed rats, Auton Neurosci, 145 (2009) 104.
43. Colucci V J & Berry B D, Heart failure worsening and exacerbation after venlafaxine and duloxetine therapy, Ann Pharmacother, 42 (2008) 882.
44. Stevens D L, Duloxetine-associated tachycardia, Ann Pharmacother, 42 (2008) 1511.
45. Shyu K G, Kuan P, Chang M L, Wang B W & Huang F Y, Effects of norepinephrine on apoptosis in rat neonatal cardiomyocytes, J Formos Med Assoc, 99 (2000) 412.
46. Neri M, Cerretani D, Fiaschi A I, Laghi P F, Lazzerini P E, Maffione A B, Micheli L, Bruni G, Nencini C, Giorgi G, D'Errico S, Fiore C, Pomara C, Riezzo I, Turillazzi E & Fineschi V, Correlation between cardiac oxidative stress and myocardial pathology due to acute and chronic norepinephrine administration in rats, J Cell Mol Med, 11 (2007) 156.